Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 4/20 | 0.51 |
| ▸ | MMP8 | P22894 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422649 | 0.77 | BTK (0.44) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL11319685 | 0.75 | MMP2 (0.52) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL22191830 | 0.74 | PARP1 (0.54) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL22191835 | 0.74 | NPC1 (0.53) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL28013683 | 0.73 | MEN1 (0.51) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL15332287 | 0.72 | MAPT (0.47) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL10589328 | 0.71 | SCN2A (0.48) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL15332513 | 0.71 | MAPT (0.46) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL6327841 | 0.71 | NPC1 (0.72) | MAPTRAB9ANPC1MMP2MMP9 | |
| SCHEMBL31474746 | 0.71 | NPC1 (0.72) | MAPTRAB9ANPC1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7182934-B2 | Ultrasonic contrast agents; aqueous suspension | GE HEALTHCARE AS (NO) | 2007-02-27 | — | — | US | disclosed |
| EP-0971747-B1 | CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2005-12-28 | — | — | EP | disclosed |
| US-20050201930-A1 | Contrast agents | GE HEALTHCARE AS (NO) | 2005-09-15 | — | — | US | disclosed |
| US-6921525-B2 | Contrast agents | AMERSHAM HEALTH AS (NO) | 2005-07-26 | — | — | US | disclosed |
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AMERSHAM HEALTH AS (NO) | 2003-12-11 | — | — | US | disclosed |
| US-6524552-B2 | Imaging cardiovascular disorders | GE HEALTHCARE AS (NO) | 2003-02-25 | — | — | US | disclosed |
| US-20010016587-A1 | Contrast agents | NYCOMED IMAGING AS | 2001-08-23 | — | — | US | disclosed |
| US-6264914-B1 | CONTAINING IMIDAZOLE RING | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| EP-0971747-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998018496-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
| EP-0028834-B1 | IMIDAZOLE-5-ACETIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-01-18 | — | — | EP | disclosed |
| US-4355040-A | Hypotensive imidazole-5-acetic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-10-19 | — | — | US | disclosed |
| EP-0028834-A1 | Imidazole-5-acetic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AGTR1, AGTR2, AGT | MAPT 3399/4885RAB9A 3060/4885NPC1 2884/4885 |
| US-20010016587-A1 | Contrast agents | AGTR1, AGTR2, VIPR1 | MAPT 2256/4885RAB9A 3055/4885NPC1 1915/4885 |
| US-20050201930-A1 | Contrast agents | AGTR1, AGTR2, VIPR1 | MAPT 2734/4885RAB9A 3503/4885NPC1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.